Expertise in
2
conditions

Stephen B. Ting

55 Commercial Road, 
Melbourne, VIC, AU 
Expertise in
2
conditions
55 Commercial Road, 
Melbourne, VIC, AU 

Overview

Stephen Ting practices practicing medicine in Melbourne, Australia.

Mr. Ting is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Primary Amyloidosis, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

55 Commercial Road, Melbourne, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
View 1 Less Clinical Trial

43 Total Publications

Thrombopoietin Receptor Agonists Plus Immunosuppressive Therapy in Aplastic Anaemia: A Systematic Review and Meta-Analysis.
Thrombopoietin Receptor Agonists Plus Immunosuppressive Therapy in Aplastic Anaemia: A Systematic Review and Meta-Analysis.
Journal: EJHaem
Published: December 15, 2025

Frequently Asked Questions about Stephen B. Ting

Is Stephen B. Ting a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Stephen B. Ting is classified as an Advanced expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stephen B. Ting participate in research or clinical trials?

Yes. Stephen B. Ting has published 43 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Stephen B. Ting's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ting's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile